60748-45-0
Chemical Structure
ATX-II
- CAS No.: 60748-45-0
- Formula:C213H323N63O61S6
- Molecular Weight:4934.62
SMILES: O=C(CN)N[C@H](C(N1[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N2[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N3[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H]4CC(N)=O)=O)CC5=CNC=N5)=O)CC6=CNC7=CC=CC=C67)=O)=O)CO)=O)CCC3)=O)CSSC[C@H](NC8=O)C(N[C@H](C(N[C@H](C(O)=O)CCC(N)=O)=O)CCCCN)=O)=O)=O)C)=O)CC(C)C)=O)CC9=CNC%10=CC=CC=C9%10)=O)[C@H](CC)C)=O)[C@H](CC)C)=O)=O)CO)=O)CC(C)C)=O)[C@@H](C)O)=O)CC(N)=O)=O)=O)CCCNC(N)=N)=O)C(C)C)=O)CO)=O)CCC2)=O)=O)CC(O)=O)=O)CO)=O)CC(O)=O)=O)CSSC[C@H](NC4=O)C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N%11[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H]%12CC%13=CNC%14=CC=CC=C%13%14)=O)=O)[C@H](CC)C)=O)[C@@H](C)O)=O)CCC%11)=O)=O)CC%15=CNC=N%15)=O)CCCCN)=O)CCCCN)=O)=O)CC(C)C)=O)CSSC[C@@H]8NC%12=O)=O)CCC1)=O)C(C)C
Biological Activity: ATX-II is a selective sodium channel modulator toxin. ATX-II enhances late sodium current, prevents full sodium channel inactivation, and generates persistent current fractions. ATX-II has pro-arrhythmic effect. ATX-II slows intrinsic heart rate, prolongs QT interval and sinus node recovery time, and causes sinus pauses and arrests. ATX-II can be used for the research of atrial fibrillation, long QT syndrome, and long QT3 syndrome[1][2][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ATX-II | 97.07% | ATX-II is a selective sodium channel modulator toxin. ATX-II enhances late sodium current, prevents full sodium channel inactivation, and generates persistent current fractions. ATX-II has pro-arrhythmic effect. ATX-II slows intrinsic heart rate, prolongs QT interval and sinus node recovery time, and causes sinus pauses and arrests. ATX-II can be used for the research of atrial fibrillation, long QT syndrome, and long QT3 syndrome. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Lu YY, et al. ATX-II-induced pulmonary vein arrhythmogenesis related to atrial fibrillation and long QT syndrome. Eur J Clin Invest. 2012;42(8):823-831. [Content Brief]
- [2]. Wu J, et al. Sinus node dysfunction in ATX-II-induced in-vitro murine model of long QT3 syndrome and rescue effect of ranolazine. Prog Biophys Mol Biol. 2008;98(2-3):198-207. [Content Brief]
- [4]. Liang F, et al. Inhibitions of late INa and CaMKII act synergistically to prevent ATX-II-induced atrial fibrillation in isolated rat right atria. J Mol Cell Cardiol. 2016 May;94:122-130. [Content Brief]
Keywords
